Plain-English translation of NCT04456816 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called AP1189 to see if it can help people with a specific type of kidney disease called idiopathic membranous nephropathy. The study will compare the medication against a placebo (a dummy pill) over 12 weeks in people who are already taking blood pressure medications. Researchers want to understand whether this treatment is safe, well-tolerated, and effective at reducing the amount of protein lost in urine.
Idiopathic membranous nephropathy causes the kidneys to leak dangerous amounts of protein into the urine, which current treatments don't always control well enough. This medication is being tested to see if it could offer a new way to help patients whose kidneys continue to leak protein despite being on standard blood pressure medications.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take one tablet by mouth once daily for 12 weeks—either the new medication or a placebo, decided randomly. You'll be part of a larger group of patients across Denmark, Norway, and Sweden, all following the same schedule alongside your regular blood pressure medications. The study includes screening visits, baseline assessments, and follow-up visits to check your safety, blood work, and urine protein levels.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Denmark